AAP: Starpharma licenses VivaGel BV in Aust, NZ

9 March 2016

"Starpharma is letting Aspen Pharmacare Australia market and distribute its Vivagel BV treatment in Australia and New Zealand for an undisclosed sum. Aspen will market and distribute the treatment for bacterial vaginosis, that's due to be launched in 2016, to clinicians and pharmacies. In return, Starpharma will receive royalties on net sales.

Starpharma still holds the commercialisation rights in the rest of the world."

Go to the article (external link)


About Starpharma

This document contains Forward Looking Statements

For Further Information


© Starpharma Holdings Limited 2017